恒瑞医药(01276.HK)： HRS-6208 胶囊、HRS-6209 胶囊、HRS-8080 片、HRS-1358 片、HRS-5041 片获批开展临床试验

Core Viewpoint - Heng Rui Medicine (01276.HK) has received approval from the National Medical Products Administration for clinical trial notifications for multiple drug candidates, indicating progress in its research and development pipeline [1] Group 1: Company Developments - The company and its subsidiaries, Shanghai Heng Rui Medicine Co., Ltd., Shandong Shengdi Medicine Co., Ltd., and Chengdu Shengdi Medicine Co., Ltd., have been granted approval for clinical trials of HRS-6208 capsules, HRS-6209 capsules, HRS-8080 tablets, HRS-1358 tablets, and HRS-5041 tablets [1]